Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 6/20 | 0.43 |
| ▸ | MAOA | P21397 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9185281 | 0.90 | IDO1 (0.42) | NPC1RAB9ASMN1; SMN2IDO1TAAR1 | |
| SCHEMBL2366928 | 0.87 | GFER (0.45) | NPC1RAB9AMAOBMAOASMN1; SMN2 | |
| SCHEMBL2252126 | 0.80 | IDO1 (0.53) | MAOBMAOAIDO1 | |
| SCHEMBL17398452 | 0.79 | IDO1 (0.47) | MAOBMAOAIDO1 | |
| SCHEMBL10314175 | 0.78 | DUT (0.33) | SMN1; SMN2IDO1 | |
| SCHEMBL5280684 | 0.78 | MAOB (0.44) | RAB9AMAOBMAOASMN1; SMN2IDO1 | |
| SCHEMBL17299381 | 0.78 | LTA4H (0.50) | MAOBSLC6A2 | |
| SCHEMBL14832628 | 0.78 | MAOB (0.43) | NPC1RAB9AMAOBMAOAIDO1 | |
| SCHEMBL16307320 | 0.78 | IDO1 (0.46) | IDO1 | |
| SCHEMBL17760802 | 0.78 | IDO1 (0.46) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662193-B2 | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662193-B2 | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins | APP, BACE1, PSEN1 | NPC1 294/4885RAB9A 3242/4885MAOB 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.